Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989564
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organi ....State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organisations will considerably enhance the productivity of these researchers, increase their collaborative and scientific outputs and allow for training of students in the latest technologies. The facility will provide researchers with cutting-edge instrumentation for nationally and internationally important projects that would benefit human health.Read moreRead less
The Role Of Capsid Protein Nucleolar Localisation In Chikungunya Virus: Implications For Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$520,520.00
Summary
Chikungunya virus (CHIKV) is a globally widespread mosquito-borne alphavirus capable of causing considerable human morbidity and mortality. With no CHIKV vaccine or antiviral available this proposal aims to develop a live attenuated CHIKV vaccine, rationally designed by investigating the host cell nucleolar trafficking of CHIKV capsid protein. This vaccine has the potential to provide cross-protection against additional arthritogenic alphaviruses endemic to Australia such as Ross River virus.
Mosquito-borne alphaviruses such as Ross River and chikungunya viruses cause widespread epidemics and exert extreme pressure on the public health systems of affected regions. Alphaviruses spreads to joints and triggers a severe disease in those affected. There are no effective treatments or vaccines. The project will investigate virus-host interaction at the bite site. The outcome will be new knowledge to treat infection at the mosquito bite site to prevent joint disease.
Novel Insights Into The Pathobiology Of Alphavirus Infections
Funder
National Health and Medical Research Council
Funding Amount
$827,660.00
Summary
Infections with mosquito-borne viruses are increasing at an alarming rate worldwide. Ross River virus is endemic in parts of Australia, PNG and Pacific islands, while chikungunya virus is distributed globally and causes recurrent pandemics that involve millions of people. These viruses cause severe musculoskeletal disease for several months after infection. This project aims to establish how these viruses interact with the human host to cause disease and may provide a basis for new treatments.